NCT07913672
A Study of LBP-MARCO and Ruxolitinib in People With Graft-Versus-Host Disease (GVHD)
StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
incidence and severity of SAEs
Timeframe: up to 100 days
Secondary (1)
Microbiota engraftment/PK
Arms and interventions
Consortia AExperimental
Participants in Cohort 1 will receive LBP-MARCO with the same combination of 7 specific types of bacteria.
Consortia BExperimental
If the bacteria do not grow or produce enough metabolites, the next group of participants (Cohort 2) will get LBP-MARCO with a different combination of bacteria.
Consortia CExperimental
If that combination does not grow in participants' guts, the next group of participants (Cohort 3) will get LBP-MARCO with a different combination of the bacteria.
Drugs: Ruxolitinib
Other: LBP- MARCO
Sites
7 sites in 1 country